Hill Tanner K, Davis Amanda L, Wheeler Frances B, Kelkar Sneha S, Freund Erica C, Lowther W Todd, Kridel Steven J, Mohs Aaron M
Department of Pharmaceutical Sciences, Biochemistry and Molecular Biology and the Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center , Omaha, Nebraska 68198, United States.
Mol Pharm. 2016 Mar 7;13(3):720-8. doi: 10.1021/acs.molpharmaceut.5b00447. Epub 2016 Feb 8.
Fatty acid synthase (FASN), the enzyme that catalyzes de novo synthesis of fatty acids, is expressed in many cancer types. Its potential as a therapeutic target is well recognized, but inhibitors of FASN have not yet been approved for cancer therapy. Orlistat (ORL), an FDA-approved lipase inhibitor, is also an effective inhibitor of FASN. However, ORL is extremely hydrophobic and has low systemic uptake after oral administration. Thus, new strategies are required to formulate ORL for cancer treatment as a FASN inhibitor. Here, we report the development of a nanoparticle (NP) formulation of ORL using amphiphilic bioconjugates that are derived from hyaluronic acid (HA), termed Nano-ORL. The NPs were loaded with up to 20 wt % weight of ORL at greater than 95% efficiency. The direct inhibition of the human recombinant thioesterase domain of FASN by ORL extracted from Nano-ORL was similar to that of stock ORL. Nano-ORL demonstrated a similar ability to inhibit cellular FASN activity when compared to free ORL, as demonstrated by analysis of (14)C-acetate incorporation into lipids. Nano-ORL treatment also disrupted mitochondrial function similarly to ORL by reducing adenosine triphosphate turnover in MDA-MB-231 and LNCaP cells. Nano-ORL demonstrated increased potency compared to ORL toward prostate and breast cancer cells. Nano-ORL decreased viability of human prostate and breast cancer cell lines to 55 and 57%, respectively, while free ORL decreased viability to 71 and 79% in the same cell lines. Moreover, Nano-ORL retained cytotoxic activity after a 24 h preincubation in aqueous conditions. Preincubation of ORL dramatically reduced the efficacy of ORL as indicated by high cell viability (>85%) in both breast and prostate cell lines. These data demonstrate that NP formulation of ORL using HA-derived polymers retains similar levels of FASN, lipid synthesis, and ATP turnover inhibition while significantly improving the cytotoxic activity against cancer cell lines.
脂肪酸合酶(FASN)是催化脂肪酸从头合成的酶,在多种癌症类型中均有表达。其作为治疗靶点的潜力已得到充分认可,但FASN抑制剂尚未获批用于癌症治疗。奥利司他(ORL)是一种经美国食品药品监督管理局(FDA)批准的脂肪酶抑制剂,也是一种有效的FASN抑制剂。然而,ORL具有极强的疏水性,口服后全身吸收率较低。因此,需要新的策略来将ORL制成用于癌症治疗的FASN抑制剂。在此,我们报告了一种使用源自透明质酸(HA)的两亲性生物共轭物制备的ORL纳米颗粒(NP)制剂,称为纳米ORL。这些纳米颗粒以大于95%的效率负载了高达20 wt%的ORL。从纳米ORL中提取的ORL对人重组FASN硫酯酶结构域的直接抑制作用与原液ORL相似。通过分析(14)C-乙酸掺入脂质的情况表明,与游离ORL相比,纳米ORL在抑制细胞FASN活性方面表现出相似的能力。纳米ORL处理还通过降低MDA-MB-231和LNCaP细胞中的三磷酸腺苷周转率,与ORL类似地破坏了线粒体功能。与ORL相比,纳米ORL对前列腺癌和乳腺癌细胞显示出更高的效力。纳米ORL分别将人前列腺癌和乳腺癌细胞系的活力降低至55%和57%,而游离ORL在相同细胞系中将活力降低至71%和79%。此外,纳米ORL在水性条件下预孵育24小时后仍保留细胞毒性活性。ORL的预孵育显著降低了ORL的疗效,这在乳腺癌和前列腺癌细胞系中均表现为高细胞活力(>85%)。这些数据表明,使用源自HA的聚合物对ORL进行纳米颗粒制剂处理,在保留相似水平的FASN、脂质合成和ATP周转率抑制作用的同时,显著提高了对癌细胞系的细胞毒性活性。